Results

Akari Therapeutics plc

07/02/2026 | Press release | Distributed by Public on 07/02/2026 15:25

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 30, 2026, Akari Therapeutics, Plc (the "Company") held its Annual General Meeting. Proxies were solicited pursuant to the Company's Proxy Statement, with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of ordinary shares entitled to vote at the Annual General Meeting was 140,032,769,533. The number of ordinary shares present or represented by valid proxy at the Annual General Meeting established a quorum for the Annual General Meeting. The Annual General Meeting duly proceeded in accordance with the provisions of the articles of association of the Company.

The voting results below are final and reported in ordinary shares.

Ordinary Resolution For Against Abstain
To receive the report of the Board of Directors and the accounts for the year ended December 31, 2025, together with the report of the statutory auditor and the strategic report. 59,475,894,977 160,000 152,962,489
To approve, on an advisory-basis, the Board of Directors' Remuneration Report (excluding the Board of Directors' Remuneration Policy), as set out in the Company's annual report and accounts for the financial year ended December 31, 2025. 41,140,049,749 944,080,000 17,544,887,717
To approve, the Directors' Remuneration Policy, as set out in the Company's annual report and accounts for the financial year ended December 31, 2025. 38,441,889,749 3,648,160,000 17,538,967,717
To re-elect Hoyoung Huh as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Company's articles of association (the "Articles"). 31,783,014,977 5,492,720,000 22,353,282,489
To re-elect Robert Bazemore as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles. 41,548,134,977 553,840,000 17,527,042,489
To re-elect James Neal as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles. 13,069,414,977 29,032,560,000 17,527,042,489
To re-elect Sandip I. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles. 41,560,694,977 541,280,000 17,527,042,489
To re-elect Samir R. Patel as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles. 41,560,694,977 529,680,000 17,538,642,489
To re-elect Abizer Gaslightwala as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles. 42,095,414,977 480,000 17,533,122,489
To ratify the appointment of BDO USA, P.C. as independent registered public accounting firm of Akari for the year ending December 31, 2026. 59,487,814,977 160,000 141,042,489
To re-appoint HaysMac LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders. 59,457,974,977 29,840,000 141,202,489
To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors' remuneration. 58,806,054,977 666,320,000 156,642,489
To approve, on a non-binding, advisory basis, the compensation of our named executive officers ("NEOs") as disclosed in the Proxy Statement. 38,483,569,749 3,600,320,000 17,545,127,717
Akari Therapeutics plc published this content on July 02, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 02, 2026 at 21:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]